Alto Neuroscience financials
$26.58−0.30%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$29.1M | -$27.1M | -$17.1M | -$15.0M | -$18.7M | -$15.7M | -$17.0M | -$18.9M | -$18.3M | -$14.4M |
| Net income | -$27.6M | -$26.2M | -$16.2M | -$14.2M | -$17.7M | -$15.2M | -$15.2M | -$16.8M | -$16.0M | -$13.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.65 | $-0.80 | $-0.47 | $-0.52 | $-0.65 | $-0.56 | $-0.56 | $-0.62 | $-0.60 | $-0.76 |
| EBITDA | -$28.9M | -$27.0M | -$16.9M | -$14.8M | -$18.5M | -$15.5M | -$16.8M | -$18.8M | -$18.2M | -$14.3M |
| Operating cash flow | -$19.8M | -$27.1M | -$11.5M | -$9.9M | -$13.8M | -$16.6M | -$13.0M | -$11.7M | -$11.7M | -$11.0M |
| Free cash flow | -$19.8M | -$27.6M | -$11.5M | -$9.9M | -$13.8M | -$16.6M | -$13.5M | -$12.7M | -$12.0M | -$11.2M |
| Diluted shares | 42.8M | 32.9M | 34.2M | 27.1M | 27.1M | 27.0M | 26.9M | 27.0M | 26.9M | 17.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $243.7M | $263.8M | $176.5M | $137.8M | $147.6M | $160.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $18.7M | $18.4M | $19.0M | $22.4M | $22.1M | $21.2M |
| Total assets | $254.1M | $276.3M | $184.7M | $147.0M | $157.9M | $171.9M |
| Total liabilities | $34.8M | $32.9M | $33.5M | $35.4M | $34.5M | $32.8M |
| Shareholders' equity | $219.2M | $243.4M | $151.1M | $111.6M | $123.4M | $139.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology